Teva Pharma S.L.U. v. Bristol-Myers Squibb Holdings Ireland Unlimited Company European Patent Convention, Arts. 54(1), 56, 63(1), 83, 87(1)(b) et al. “Plausibility Test”. // IIC - International Review of Intellectual Property and Competition Law. – 2026. – DOI: 10.1007/s40319-026-01707-8. – URL: https://doi.org/10.1007/s40319-026-01707-8
Teva Pharma S.L.U. v. Bristol-Myers Squibb Holdings Ireland Unlimited Company European Patent Convention, Arts. 54(1), 56, 63(1), 83, 87(1)(b), 89, 123(2), 138(1); Supplementary Protection Certificate Regulation, Art. 4(A)(1); Spanish Civil Code, & Art. 4(2) (2026). “Plausibility Test”. IIC - International Review of Intellectual Property and Competition Law. https://doi.org/10.1007/s40319-026-01707-8
Teva Pharma S.L.U. v. Bristol-Myers Squibb Holdings Ireland Unlimited Company European Patent Convention, et al. ““Plausibility Test”.” IIC - International Review of Intellectual Property and Competition Law, 2026. doi:10.1007/s40319-026-01707-8.
@article{Convention2026,
title = {“Plausibility Test”},
author = {Convention, Teva Pharma S.L.U. v. Bristol-Myers Squibb Holdings Ireland Unlimited Company European Patent and 54(1), Arts. and 56 and 63(1) and 83 and 87(1)(b) and 89 and 123(2) and Regulation, 138(1); Supplementary Protection Certificate and Code, Art. 4(A)(1); Spanish Civil and 4(2), Art.},
journal = {IIC - International Review of Intellectual Property and Competition Law},
year = {2026},
doi = {10.1007/s40319-026-01707-8},
url = {https://doi.org/10.1007/s40319-026-01707-8}
}